



NEWS RELEASE

# CareDx Presents the Latest AlloSure Data in Virtual Meetings

2020-05-27

Leading transplant clinicians to present ten abstracts accepted for presentation at the  
American Transplant Congress

SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced today the delivery of content on state-of-the-art research accepted at the American Transplant Congress (ATC) annual meeting scheduled for May 30-June 1, 2020.

CareDx's program will include two virtual abstract sessions with prominent authors delivering ten abstracts accepted for presentation at the ATC Annual Scientific Sessions. A virtual symposium will also be held with leaders in the field of transplantation delivering cutting edge content on AlloSure, AlloMap, iBox, and KidneyCare. Additionally, CareDx will host a Transplant Celebration event with performances from the transplant community and a telemedicine panel with the CEO of Doxy.me. Registration information for CareDx virtual programming can be found at [caredx.com/atc](https://caredx.com/atc).

On Thursday, May 28, 2020, 3:00 PM EDT, five abstracts will be presented:

- Role of Cell Free DNA (AlloSure) Testing in Recipients of Kidneys with Sub Optimal Donor Quality – Yasir Qazi, MD, Keck, University of Southern California
- Characterization of An Integrative Prognostic Score For U.S. Patients Taken From the Dart Study – Abdolreza Haririan, MD, University of Maryland
- Donor-derived Cell-free DNA For Detection Of Cell-mediated Rejection In Low Risk Kidney Transplant Patients

– Sanjiv Anand, Intermountain Medical Center

- Center Experience with dd-cfDNA in Lung Transplantation – Deborah Jo Levine, MD, UT Health San Antonio
- Impact of Kidney Transplant Type and Previous Transplant on Baseline Donor-derived Cell-free DNA – Kalathil Sureshkumar, MD, Allegheny

On Friday, May 29, 2020, 3:00 PM EDT, a virtual symposium on COVID-19 in Transplant, Telemedicine, and AlloSure clinical data and case examples will be presented, chaired by Manikkam Suthanthiran, MD, Weill Cornell Medicine and featuring the following speakers:

- Hannah A. Valantine, MD, NIH
- Marlon Levy, MD, Virginia Commonwealth University
- Nicolae Leca, MD, University of Washington
- Robert Stratta, MD, Wake Forest
- Stanley Jordan, MD, Cedars Sinai
- George Burke, MD, Jackson Memorial

On Friday, May 29, 2020 5:00 PM EDT CareDx will be hosting a press conference on the latest innovations in transplantation with the following speakers:

- Peter Maag PhD, CEO and Chairman at CareDx
- David Guthrie, Chief Product Officer Patient Point and lung transplant recipient
- Medhat Askar, MD, PhD, Baylor University Medical Center
- Alexandre Loupy, MD, PhD, Paris Transplant Group

On Tuesday, June 2, 2020, 3:00 PM EDT, five abstracts will be presented:

- The Use of AlloSure Donor Derived Cell-free DNA in a Community Based Kidney Transplant Program – Velma P. Scantlebury, MD, ChristianaCare
- Peds Post Rejection Treatment, Biopsy Proven (Both T Cell And B Cell) Looking at AlloSure 3 Months Post, Along with AT1R and DSA – Dechu Puliyananda, MD, Cedars Sinai
- Value of dd-cfDNA When Considering Recipient Ethnicity to Further Help Risk Stratify Transplant Recipients – Anthony Langone, MD, Vanderbilt
- Utility of dd-cfDNA in TCMR 1A and Borderline Allograft Rejection – Erik Stites, MD, UCHealth
- Characterization of an Integrative Prognostic Score for US Patients Taken from the Dart Study – Daniel Brennan, MD, Johns Hopkins

“We look forward to contributing to the virtual ATC meeting and continuing to drive innovation in transplant by sharing these latest abstracts virtually. This is a critical time for the transplant community to come together, and we are creating a space for shared experiences and learning,” says Peter Maag, CEO of CareDx.

## About CareDx

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: [www.CareDx.com](http://www.CareDx.com).

## CONTACTS:

CareDx, Inc.

Sasha King

Chief Marketing Officer

415-287-2393

[sking@caredx.com](mailto:sking@ caredx.com)

Investor Relations

Greg Chodaczek

646-924-1769

[investor@caredx.com](mailto:investor@caredx.com)

Source: CareDx, Inc.